Protagonist Therapeutics (PTGX)
(Delayed Data from NSDQ)
$47.33 USD
+1.41 (3.07%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $47.33 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Earnings News For PTGX
-
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates
-
Protagonist Therapeutics: Q2 Earnings Snapshot
-
Protagonist Therapeutics: Q1 Earnings Snapshot
-
Protagonist Therapeutics: Q4 Earnings Snapshot
-
Protagonist Therapeutics: Q3 Earnings Snapshot
-
Protagonist Therapeutics: Q1 Earnings Snapshot
-
Protagonist Reports First Quarter 2023 Financial Results and Provides Corporate Update
-
Protagonist Therapeutics: Q4 Earnings Snapshot
-
Protagonist Therapeutics: Q3 Earnings Snapshot
-
Protagonist Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates
-
Protagonist Therapeutics: Q2 Earnings Snapshot
-
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
-
Protagonist Therapeutics (PTGX) Reports Q4 Loss, Tops Revenue Estimates
-
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates
-
Analysts Estimate Protagonist Therapeutics (PTGX) to Report a Decline in Earnings: What to Look Out for
-
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates
-
Will Protagonist Therapeutics (PTGX) Report Negative Q2 Earnings? What You Should Know
-
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
-
Protagonist Therapeutics (PTGX) Reports Q4 Loss, Tops Revenue Estimates
-
Will Protagonist Therapeutics (PTGX) Report Negative Q4 Earnings? What You Should Know
-
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates
-
Protagonist Therapeutics (PTGX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
-
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Tops Revenue Estimates
-
Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release